Levosimendan Kabi

Levosimendan, the active ingredient in Levosimendan Kabi, is a calcium sensitizer presented as an injectable solution for intravenous use. It is employed to improve cardiac performance in patients with acute decompensated heart failure. GNH USA supplies Levosimendan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is used in the management of heart failure syndromes where enhanced contractility and vasodilation are required. Acute decompensated heart failure: improves cardiac output and relieves congestion. Chronic heart failure with low output: provides inotropic support as an adjunct to standard therapy.

Levosimendan may be associated with several adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Nausea or vomiting: gastrointestinal discomfort. - Dizziness: related to blood pressure changes. - Tachycardia: increased heart rate. - Arrhythmias: occasional premature beats.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Ventricular arrhythmias: potentially life‑threatening. - Myocardial ischemia: chest pain or ECG changes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Hepatic enzyme elevation: abnormal liver function tests. - Thrombocytopenia: reduced platelet count.

Levosimendan requires careful monitoring and specific safety measures. - Blood pressure monitoring: watch for hypotension during infusion. - Cardiac rhythm surveillance: observe for arrhythmias. - Contraindication in severe hypotension: avoid use when systolic BP <90 mmHg. - Adjust in renal/hepatic impairment: dose may need modification. - Caution with mechanical obstruction: do not use in patients with outflow tract obstruction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levosimendan can interact with several drug classes, influencing safety and efficacy.

Major Interactions (Avoid): - Concurrent strong vasodilators (e.g., nitroglycerin): risk of profound hypotension. - Other inotropic agents (e.g., dobutamine): may precipitate arrhythmias.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt inotropic response. - ACE inhibitors or ARBs: additive blood‑pressure lowering effect. - Diuretics: can exacerbate volume depletion. - Calcium channel blockers: may affect vascular tone. - CYP450 inhibitors (e.g., ketoconazole): potential increase in plasma levosimendan levels.